PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32354665-3 2020 METHODS: Twelve Parkinson"s disease (PD) patients suffering from levodopa-responsive-FoG (off-FoG) were compared with 12 PD patients without FoG and 12 healthy subjects of similar age/sex. Levodopa 65-73 zinc finger protein, FOG family member 1 Homo sapiens 85-88 33279909-10 2021 CONCLUSIONS: PPN-DBS remains an investigational treatment for levodopa-refractory FOG. Levodopa 62-70 zinc finger protein, FOG family member 1 Homo sapiens 82-85 33027712-2 2020 The sensitivity of these situations to detect FOG and the relative FOG response to l-dopa and subthalamic nucleus deep brain stimulation (STN-DBS) is unknown. Levodopa 83-89 zinc finger protein, FOG family member 1 Homo sapiens 67-70 33027712-14 2020 STN-DBS and l-dopa improve all FOG subtypes similarly, their effect is stronger in combination. Levodopa 12-18 zinc finger protein, FOG family member 1 Homo sapiens 31-34 34011807-6 2021 After reducing the levodopa equivalent dose to control the dyskinesia to an almost negligible level, his FOG also improved and his activities of daily living improved markedly. Levodopa 19-27 zinc finger protein, FOG family member 1 Homo sapiens 105-108 33011852-9 2021 Participant #2, walking FOG frequency and turning duration was reduced by 39.0% (OFF-L-dopa), and ON-L-dopa UPDRS-III score worsened (+ 5 points) at 12 months. Levodopa 85-91 zinc finger protein, FOG family member 1 Homo sapiens 24-27 33230756-6 2021 PD patients with FOG were older and had longer disease duration, higher levodopa equivalent dose, higher modified Hoehn and Yahr stage, higher Unified PD Rating Scale motor score, higher FOG-Q score, higher total Non-Motor Symptom Scale score, and lower BMD scores in the femoral neck area than those without FOG. Levodopa 72-80 zinc finger protein, FOG family member 1 Homo sapiens 17-20 32333181-9 2020 FOG was related to functional dependency (OR = 3.470; 95%CI 1.411-8.530; p = 0.007) after adjustment to age, gender, disease duration, daily equivalent levodopa dose, comorbidity (number of non-antiparkinsonian drugs/day), motor status (UPDRS-III), PIGD phenotype, motor complications (UPDRS-IV), NMS burden (NMSS total score), cognition (PD-CRS), and mood (BDI-II). Levodopa 152-160 zinc finger protein, FOG family member 1 Homo sapiens 0-3 32431656-6 2020 We correlated the FoG outcome, calculated as improvement of Freezing of Gait Assessment Course (FoG-AC) from baseline MedOff to 6-month follow-up MedOn/StimOn, with the levodopa response of preoperative clinical and kinematic gait measures. Levodopa 169-177 zinc finger protein, FOG family member 1 Homo sapiens 18-21 32509261-4 2020 Objective: To study the effects of intestinal levodopa/carbidopa infusion in unresponsive-FOG that appears in PD patients treated with subthalamic nucleus deep brain stimulation. Levodopa 46-54 zinc finger protein, FOG family member 1 Homo sapiens 90-93 32509261-7 2020 Results: Administration of intestinal levodopa caused improvement of FOG in the "ON" state in four patients (80%) by 2 or more points in item 14 of the Unified Parkinson"s Disease Rating Scale. Levodopa 38-46 zinc finger protein, FOG family member 1 Homo sapiens 69-72 32509261-9 2020 Conclusions: Intestinal levodopa infusion may be a valuable therapeutic option for unresponsive-FOG developed after subthalamic nucleus deep brain stimulation. Levodopa 24-32 zinc finger protein, FOG family member 1 Homo sapiens 96-99 32431656-6 2020 We correlated the FoG outcome, calculated as improvement of Freezing of Gait Assessment Course (FoG-AC) from baseline MedOff to 6-month follow-up MedOn/StimOn, with the levodopa response of preoperative clinical and kinematic gait measures. Levodopa 169-177 zinc finger protein, FOG family member 1 Homo sapiens 96-99 32431656-8 2020 Results: We found that the postoperative gait and FoG outcomes were associated with the preoperative levodopa response of clinical and kinematic gait measures. Levodopa 101-109 zinc finger protein, FOG family member 1 Homo sapiens 50-53 32431656-9 2020 In particular, preoperative levodopa sensitivity of FoG showed high correlation with a favorable quantitative FoG outcome. Levodopa 28-36 zinc finger protein, FOG family member 1 Homo sapiens 52-55 32431656-9 2020 In particular, preoperative levodopa sensitivity of FoG showed high correlation with a favorable quantitative FoG outcome. Levodopa 28-36 zinc finger protein, FOG family member 1 Homo sapiens 110-113 32431656-10 2020 Among kinematic measures, preoperative levodopa response of stride length and range of motion showed high correlation with favorable FoG outcome. Levodopa 39-47 zinc finger protein, FOG family member 1 Homo sapiens 133-136 32431656-11 2020 In addition, the preoperative levodopa sensitivity of FoG predicted postoperative FoG outcome with high accuracy (R 2 = 0.952; 95% CI: 0.95-1.29; P < 0.001). Levodopa 30-38 zinc finger protein, FOG family member 1 Homo sapiens 54-57 32431656-11 2020 In addition, the preoperative levodopa sensitivity of FoG predicted postoperative FoG outcome with high accuracy (R 2 = 0.952; 95% CI: 0.95-1.29; P < 0.001). Levodopa 30-38 zinc finger protein, FOG family member 1 Homo sapiens 82-85 32322387-7 2020 Despite the limited effectiveness of current medications for FOG, especially levodopa resistant FOG, there were some drugs that showed promise such as istradefylline and rasagiline. Levodopa 77-85 zinc finger protein, FOG family member 1 Homo sapiens 96-99 31799377-1 2019 Study objectives included testing whether presumed levodopa-unresponsive freezing of gait (FOG) in Parkinson"s disease (PD) actually persists in the presence of adequate dopaminergic dosing and to investigate whether the presence of other parkinsonian features and their responsiveness to therapy varies across patients without FOG (NO-FOG), with levodopa-responsive FOG (OFF-FOG), and with levodopa-unresponsive FOG (ONOFF-FOG). Levodopa 51-59 zinc finger protein, FOG family member 1 Homo sapiens 91-94 32258233-1 2020 Background: The relationship between freezing of gait (FOG) and levodopa response is complex. Levodopa 64-72 zinc finger protein, FOG family member 1 Homo sapiens 55-58 32258233-2 2020 Some patients respond, some have no response and in some patients levodopa causes FOG. Levodopa 66-74 zinc finger protein, FOG family member 1 Homo sapiens 82-85 32258233-3 2020 We present 2 cases demonstrating a diphasic worsening of FOG after levodopa dosing. Levodopa 67-75 zinc finger protein, FOG family member 1 Homo sapiens 57-60 31866812-9 2019 Levodopa equivalent dose, age (direct), age at disease onset (inverse), and WCST were significant predictors of FoG (p = 0.01, p = 0.0025, p = 0.0016, and p = 0.029, respectively). Levodopa 0-8 zinc finger protein, FOG family member 1 Homo sapiens 112-115 31866812-11 2019 The main explanatory variables of FoG occurrence are levodopa equivalent dose, age, age at disease onset, and WCST. Levodopa 53-61 zinc finger protein, FOG family member 1 Homo sapiens 34-37 29406886-1 2018 OBJECTIVE: To determine the impact of levodopa-carbidopa intestinal gel (LCIG) infusion on different subtypes of freezing of gait (FoG) classified according to levodopa responsiveness in advanced Parkinson disease (PD) patients. Levodopa 38-46 zinc finger protein, FOG family member 1 Homo sapiens 131-134 29801899-5 2018 RESULTS: Logistic regression models controlling for age at diagnosis, sex, disease duration, and L-dopa dose revealed that 123I-FP-CIT binding in the putamen and striatum significantly predicted FOG (OR = 0.02, p = 0.03; OR = 0.01, p = 0.04; respectively) but not falls. Levodopa 97-103 zinc finger protein, FOG family member 1 Homo sapiens 195-198 31337633-4 2019 The patient clearly showed a dose-dependent paradoxical response to L-DOPA treatment with the emergence of severe FOG and postural instability. Levodopa 68-74 zinc finger protein, FOG family member 1 Homo sapiens 114-117 31275238-5 2019 Within the next 6 months and after several programming sessions, the patient reported "on" FoG occurring regularly 1 h after taking levodopa and lasting a few hours. Levodopa 132-140 zinc finger protein, FOG family member 1 Homo sapiens 91-94 31275238-6 2019 Accordingly, a repeated levodopa challenge showed that FoG resolved with either levodopa administration or STN stimulation alone, but the combination of both therapies induced recurrence of FoG in our patient. Levodopa 24-32 zinc finger protein, FOG family member 1 Homo sapiens 55-58 31275238-6 2019 Accordingly, a repeated levodopa challenge showed that FoG resolved with either levodopa administration or STN stimulation alone, but the combination of both therapies induced recurrence of FoG in our patient. Levodopa 80-88 zinc finger protein, FOG family member 1 Homo sapiens 55-58 25578290-1 2015 OBJECTIVE: We report a prospective, open label study of 24 h levodopa-carbidopa intestinal gel (LCIG) as treatment for levodopa "unresponsive" freezing of gait (FOG) associated with Parkinson"s disease. Levodopa 61-69 zinc finger protein, FOG family member 1 Homo sapiens 161-164 28855889-10 2017 l-DOPA improved gait significantly in patients with PD and particularly in patients with FOG mainly by reducing FOG duration and increasing specific spatiotemporal gait parameters. Levodopa 0-6 zinc finger protein, FOG family member 1 Homo sapiens 89-92 28855889-10 2017 l-DOPA improved gait significantly in patients with PD and particularly in patients with FOG mainly by reducing FOG duration and increasing specific spatiotemporal gait parameters. Levodopa 0-6 zinc finger protein, FOG family member 1 Homo sapiens 112-115 28855889-12 2017 Our study overall provides new information on the beneficial effect of l-DOPA on FOG severity and specific spatiotemporal gait parameters as objectively measured by a wearable sensory system. Levodopa 71-77 zinc finger protein, FOG family member 1 Homo sapiens 81-84 28251464-6 2017 Patients with FOG showed lower proportion of male, longer disease duration, lower body mass index, lower concentrations of serum UA, higher total levodopa equivalent daily dosage, higher UPDRS III score, greater median H and Y stage, lower scores of FAB and MoCA, and higher frequencies of motor fluctuation, dyskinesia, falls, and festination compared to patients without FOG (P < 0.05). Levodopa 146-154 zinc finger protein, FOG family member 1 Homo sapiens 14-17 27368041-12 2016 Scores at baseline, patients with Parkinson disease were more likely to experience FOG if: they were older, or from the countryside; had an akinetic-rigid style, anxiety, or higher NMSS scores; they used levodopa early or did not use amantadine or selegiline; their lower limbs were the site of onset; or they had more severe motor disability or higher HAMD scores at baseline. Levodopa 204-212 zinc finger protein, FOG family member 1 Homo sapiens 83-86 26635194-3 2016 Levodopa and monoamine oxidase inhibitors (rasagiline and selegiline) have shown effective improvement for FOG. Levodopa 0-8 zinc finger protein, FOG family member 1 Homo sapiens 107-110 27662331-7 2016 RESULTS: According to the available assessment tools severity of FOG is marked by one or a combination of multiple clinical expressions including frequency, duration, triggering circumstances, response to levodopa, association with falls and fear of falling, or need for assistance to avoid falls. Levodopa 205-213 zinc finger protein, FOG family member 1 Homo sapiens 65-68 27268039-2 2016 METHODS: We performed a cross-over, sham-controlled study of patients with severe PD, bilateral motor signs and debilitating, severe FoG, that was levodopa-sensitive but not controlled by optimal dopatherapy. Levodopa 147-155 zinc finger protein, FOG family member 1 Homo sapiens 133-136 27064915-1 2016 INTRODUCTION: Over recent years, several types of freezing of gait (FOG) have been described, mainly according to their response to levodopa. Levodopa 132-140 zinc finger protein, FOG family member 1 Homo sapiens 68-71 25939726-6 2015 FOG Questionnaire and UPDRS subscores related to gait and postural stability significantly improved during Levodopa-carbidopa intrajejunal gel infusion in all patients compared to O-LD treatment. Levodopa 107-115 zinc finger protein, FOG family member 1 Homo sapiens 0-3 25578290-1 2015 OBJECTIVE: We report a prospective, open label study of 24 h levodopa-carbidopa intestinal gel (LCIG) as treatment for levodopa "unresponsive" freezing of gait (FOG) associated with Parkinson"s disease. Levodopa 119-127 zinc finger protein, FOG family member 1 Homo sapiens 161-164 25578290-2 2015 METHOD: 5 patients with disabling FOG, documented as being levodopa "unresponsive", were commenced on continuous 24 h infusion LCIG therapy with the night-time rate at 50-80% of the daytime infusion rate. Levodopa 59-67 zinc finger protein, FOG family member 1 Homo sapiens 34-37 25603767-11 2015 Motor fluctuations (odds ratio (OR) 3.45; p = 0.036) and higher levodopa dose (OR 1.30/100 mg, p = 0.009) at baseline were independent risk factors of incident FOG. Levodopa 64-72 zinc finger protein, FOG family member 1 Homo sapiens 160-163 24768615-9 2014 Levodopa tended to decrease FoG and falls with or without dual tasking. Levodopa 0-8 zinc finger protein, FOG family member 1 Homo sapiens 28-31 25785228-6 2015 FOG improved with levodopa in 21/27 patients with typical PD but did not improve in the 12 patients with atypical parkinsonism. Levodopa 18-26 zinc finger protein, FOG family member 1 Homo sapiens 0-3 25446341-4 2014 Pharmacologic subtypes of FOG include those that are responsive and unresponsive to levodopa. Levodopa 84-92 zinc finger protein, FOG family member 1 Homo sapiens 26-29 25446341-5 2014 OBJECTIVE: To determine whether executive and visuospatial dysfunction are associated specifically with the levodopa unresponsive subtype of FOG. Levodopa 108-116 zinc finger protein, FOG family member 1 Homo sapiens 141-144 24396010-11 2014 STN-DBS-induced benefits on FOG were mostly mediated by baseline levodopa equivalent dose, altered medication-intake and reduced motor fluctuations. Levodopa 65-73 zinc finger protein, FOG family member 1 Homo sapiens 28-31 24367353-5 2013 In one patient levodopa treatment was initialized which was somewhat successful to relieve FOG. Levodopa 15-23 zinc finger protein, FOG family member 1 Homo sapiens 91-94 25042502-10 2014 FOG in off-periods were observed in 2/3 patients treated with levodopa, 1/3 of patients did not relate FOG with the periods of levodopa action. Levodopa 62-70 zinc finger protein, FOG family member 1 Homo sapiens 0-3 24361601-4 2014 RESULTS: p-FOG patients showed higher power in the high-beta band (F=11.6, p=0.002) that was significantly reduced after l-dopa administration along with suppression of FOG (F=4.6, p=0.042). Levodopa 121-127 zinc finger protein, FOG family member 1 Homo sapiens 11-14 24361601-4 2014 RESULTS: p-FOG patients showed higher power in the high-beta band (F=11.6, p=0.002) that was significantly reduced after l-dopa administration along with suppression of FOG (F=4.6, p=0.042). Levodopa 121-127 zinc finger protein, FOG family member 1 Homo sapiens 169-172 24132839-7 2013 The depletion of motor and cognitive reserves and an increasingly complex response to levodopa with disease progression will also have an impact on the emergence of FOG episodes. Levodopa 86-94 zinc finger protein, FOG family member 1 Homo sapiens 165-168 23115014-7 2012 The combination of the following four independent contributors provided the best explanatory model of FOG (R(2) = 0.49): nongait freezing; levodopa equivalent dose (LED); cognitive impairment; and falls and balance problems. Levodopa 139-147 zinc finger protein, FOG family member 1 Homo sapiens 102-105 23265352-8 2013 Moreover, the beneficial effect was observed only in patients with levodopa-resistant FOG. Levodopa 67-75 zinc finger protein, FOG family member 1 Homo sapiens 86-89 23265352-9 2013 This result supports our hypothesis, at least in patients with levodopa-resistant FOG, and shows that the co-administration of L-DOPS and entacapone could be a new strategy for FOG treatment. Levodopa 63-71 zinc finger protein, FOG family member 1 Homo sapiens 82-85 23265352-9 2013 This result supports our hypothesis, at least in patients with levodopa-resistant FOG, and shows that the co-administration of L-DOPS and entacapone could be a new strategy for FOG treatment. Levodopa 63-71 zinc finger protein, FOG family member 1 Homo sapiens 177-180 24403689-9 2013 This case study shows a person with PD demonstrating decreased cerebral oxygenation during FOG, which may be based on his variable response to levodopa medication or may be attributable to as yet unidentified physiologic mechanisms. Levodopa 143-151 zinc finger protein, FOG family member 1 Homo sapiens 91-94 22967858-8 2012 The development of NHP FOG was significantly associated with the severity of parkinsonism, as shown by high motor disability scores (>= 20) and levodopa-induced dyskinesia scores (p=0.01 and p=0.04, respectively). Levodopa 147-155 zinc finger protein, FOG family member 1 Homo sapiens 23-26 22262741-1 2012 OBJECTIVE: To describe the phenotype of levodopa-induced "on" freezing of gait (FOG) in Parkinson disease (PD). Levodopa 40-48 zinc finger protein, FOG family member 1 Homo sapiens 80-83 22324564-3 2012 [Correction added on 18 April 2012, after online publication: In the preceding statement, 55 instead of 54 patients with PD were evaluated, and FOG negative consisted of 34 instead of 33 patients] Furthermore, we examined rCBF in FOG-negative patients treated with levodopa with or without selegiline. Levodopa 265-273 zinc finger protein, FOG family member 1 Homo sapiens 230-233 18413568-5 2008 After surgery, STN stimulation reproduced the improvement induced by levodopa before surgery in all but two patients with FOG and five others unable to walk. Levodopa 69-77 zinc finger protein, FOG family member 1 Homo sapiens 122-125 19811797-2 2010 Double-blind clinical trials and, above all, clinical experience have demonstrated that l-DOPA is effective in reducing FOG. Levodopa 88-94 zinc finger protein, FOG family member 1 Homo sapiens 120-123 19815246-10 2010 In the rare cases of levodopa-induced FOG, STN stimulation may be indirectly effective, as it enables reduction or arrest of the levodopa treatment. Levodopa 21-29 zinc finger protein, FOG family member 1 Homo sapiens 38-41 19815246-10 2010 In the rare cases of levodopa-induced FOG, STN stimulation may be indirectly effective, as it enables reduction or arrest of the levodopa treatment. Levodopa 129-137 zinc finger protein, FOG family member 1 Homo sapiens 38-41 34915449-8 2022 RESULTS: Therapeutic effect of GPi DBS on FOG were correlated with the disease duration of PD before DBS surgery, preoperative improvement in FOG severity by levodopa medication, and the distance from active contact of DBS electrode to the prefrontal region of GPi anatomical site. Levodopa 158-166 zinc finger protein, FOG family member 1 Homo sapiens 42-45 18668617-1 2008 The majority of patients with Parkinson"s disease suffer from freezing of gait (FOG), which responds more or less to levodopa. Levodopa 117-125 zinc finger protein, FOG family member 1 Homo sapiens 80-83 18668617-4 2008 STN stimulation was reported to improve levodopa-responsive FOG. Levodopa 40-48 zinc finger protein, FOG family member 1 Homo sapiens 60-63 18668617-7 2008 In the few cases of levodopa-induced FOG, STN stimulation can indirectly be effective, thanks to a great decrease or arrest of levodopa. Levodopa 20-28 zinc finger protein, FOG family member 1 Homo sapiens 37-40 18668617-7 2008 In the few cases of levodopa-induced FOG, STN stimulation can indirectly be effective, thanks to a great decrease or arrest of levodopa. Levodopa 127-135 zinc finger protein, FOG family member 1 Homo sapiens 37-40 18668620-2 2008 Recent studies have clearly demonstrated that the Off-related FOG is improved by levodopa (L-dopa) or entacapone treatment. Levodopa 81-89 zinc finger protein, FOG family member 1 Homo sapiens 62-65 18668620-2 2008 Recent studies have clearly demonstrated that the Off-related FOG is improved by levodopa (L-dopa) or entacapone treatment. Levodopa 91-97 zinc finger protein, FOG family member 1 Homo sapiens 62-65 18668620-3 2008 L-dopa can decrease duration of each FOG episode as well as its frequency. Levodopa 0-6 zinc finger protein, FOG family member 1 Homo sapiens 37-40 12948464-7 2003 Levodopa significantly decreased FOG frequency (p<0.001). Levodopa 0-8 zinc finger protein, FOG family member 1 Homo sapiens 33-36 12948464-9 2003 CONCLUSION: Levodopa decreases FOG in PD. Levodopa 12-20 zinc finger protein, FOG family member 1 Homo sapiens 31-34 12823491-11 2003 Levodopa significantly decreased FOG frequency (P < 0.0001) and the number of episodes with akinesia (P < 0.001). Levodopa 0-8 zinc finger protein, FOG family member 1 Homo sapiens 33-36 11261746-13 2001 Severity of the disease expressed by H&Y stage at "off" was a significant contributing factor for FOG with a significant trend (z = 4.38, p < 0.0001), as was longer duration of levodopa treatment, and confirmed by FOG using the multivariate logistic regression (p = 0.01 and p = 0.004, respectively). Levodopa 177-185 zinc finger protein, FOG family member 1 Homo sapiens 98-101 34915449-8 2022 RESULTS: Therapeutic effect of GPi DBS on FOG were correlated with the disease duration of PD before DBS surgery, preoperative improvement in FOG severity by levodopa medication, and the distance from active contact of DBS electrode to the prefrontal region of GPi anatomical site. Levodopa 158-166 zinc finger protein, FOG family member 1 Homo sapiens 142-145 34915449-9 2022 CONCLUSIONS: Our study results suggest that the effect of GPi DBS on FOG is correlated with disease duration, levodopa responsiveness on FOG before DBS surgery and DBS electrode location, providing useful information to predict FOG outcome after GPi DBS in PD patients. Levodopa 110-118 zinc finger protein, FOG family member 1 Homo sapiens 69-72 34915449-9 2022 CONCLUSIONS: Our study results suggest that the effect of GPi DBS on FOG is correlated with disease duration, levodopa responsiveness on FOG before DBS surgery and DBS electrode location, providing useful information to predict FOG outcome after GPi DBS in PD patients. Levodopa 110-118 zinc finger protein, FOG family member 1 Homo sapiens 137-140 34915449-9 2022 CONCLUSIONS: Our study results suggest that the effect of GPi DBS on FOG is correlated with disease duration, levodopa responsiveness on FOG before DBS surgery and DBS electrode location, providing useful information to predict FOG outcome after GPi DBS in PD patients. Levodopa 110-118 zinc finger protein, FOG family member 1 Homo sapiens 228-231 34161592-3 2021 OBJECTIVE: To test whether bilateral stimulation centered at the fields of Forel improves levodopa unresponsive freezing of gait (FOG), balance problems, postural instability, and falls in PD. Levodopa 90-98 zinc finger protein, FOG family member 1 Homo sapiens 130-133 34078477-1 2021 BACKGROUND: Freezing of gait (FOG) is a particularly debilitating motor deficit seen in a subset of Parkinson"s disease (PD) patients that is poorly responsive to standard levodopa therapy or deep brain stimulation (DBS) of established PD targets such as the subthalamic nucleus and the globus pallidus interna. Levodopa 172-180 zinc finger protein, FOG family member 1 Homo sapiens 30-33 35398727-10 2022 Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. Levodopa 77-85 zinc finger protein, FOG family member 1 Homo sapiens 26-29 35462702-9 2022 Conclusion: FOG is a common symptom in MSA patients and it is correlated with poor quality of life, disease progression and severity, levodopa-equivalent dose, and cerebellum impairment. Levodopa 134-142 zinc finger protein, FOG family member 1 Homo sapiens 12-15